Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-?. Phase 3.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
